This integrated evidence suggests that maternal EA treatment may promote placental angiogenesis via activation of the PGF/VEGFR-1/PI3K/AKT pathway, thereby protecting against PNE-induced IUGR. The gene discussed is PIK3CA; the disease is fetal growth restriction.